Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogenicity. Both antigens were well tolerated. ALVAC-HIV (vCP205) induced low levels of neutralizing antibodies against HIV-1 MN in 33% of the volunteers. None of them had detectable neutralizing antibodies against a nonsyncytium-inducing HIV-1 clade B primary isolate (Bx08). After the fourth injection of vCP205, CTL activity was detected in 33% of the volunteers and was directed against Env, Gag, and Pol. This activity was mediated by both CD4+ and CD8+ lymphocytes. On the other hand, the CLTB-36 peptide was poorly immunogenic and induced no neutralizing antibodies or CTLs. Although the ALVAC-HIV (vCP205) and CLTB-36 prime-boost regimen was not optimal, further studies with ALVAC-HIV (vCP205) are warranted because of its clear induction of a cellular immune response and utility as a priming agent for other subunit antigens such as envelope glycoproteins, pseudoparticles, or new peptides.
Salmon-Céron
D
D
CHU Cochin AP HP, Universite Paris, France.
Excler
J L
JL
Finkielsztejn
L
L
Autran
B
B
Gluckman
J C
JC
Sicard
D
D
Matthews
T J
TJ
Meignier
B
B
Valentin
C
C
El Habib
R
R
Blondeau
C
C
Raux
M
M
Moog
C
C
Tartaglia
J
J
Chong
P
P
Klein
M
M
Milcamps
B
B
Heshmati
F
F
Plotkin
S
S
D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology*; D000328:Adult; D000595:Amino Acid Sequence; D018150:Avipoxvirus / Q000235:genetics / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000097:blood; D016655:HIV Core Protein p24 / Q000737:chemistry / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects* / Q000276:immunology*
D016915:AIDS Vaccines; C000594377:ALVAC-HIV vCP205 vaccine; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D010455:Peptides; D014614:Vaccines, Synthetic